NHD Global
Cognitive & Neuropeptides · Source-reviewed dossier
Source-Reviewed Research Dossier
Selank is a synthetic seven-amino-acid peptide (heptapeptide) loosely modeled on tuftsin, a natural immune-signaling fragment. It is studied mainly for possible effects on anxiety-related brain chemistry, particularly through GABA signaling, the same calming system targeted by benzodiazepine drugs. In one human trial, Selank was added to an existing anti-anxiety medicine; patients on the combination improved somewhat faster and had fewer typical tranquilizer side effects. A separate rat study found changes in many GABA-related genes after Selank exposure. Independent replication is scarce and some reports appear only as translated abstracts. Evidence remains limited and exploratory.
Shared values below are consolidated from the current catalog record. They are not independent verification or lot results; request the applicable product specification and ask which lot records are available before ordering.
Product identity
Literature reference parameters
Identity safeguard Reference identifiers above describe the literature compound record. Confirm the supplied form, formula, molecular weight, purity and storage conditions against the applicable product specification and any available lot records.
A target-to-pathway view grounded in the linked research records.
Reported research findings
Reported outcomes are paired with their experimental model and evidence boundary.
A 2015 publication reported Selank use in anxiety disorders.
The public record is limited and does not provide the breadth of independent replication expected for a general claim.
Read the primary studyA 2016 study reported changes in expression of genes involved in GABAergic neurotransmission after Selank exposure.
Gene-expression outcomes are mechanistic and do not establish clinical benefit.
Read the primary studyCatalog options
Pack-level catalog data; lot-level controls remain document-specific.
Single-component peptide · 5 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
Single-component peptide · 10 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
A listed document is not proof of availability for this lot. Ask the team to confirm the current COA status and the scope of any other records before ordering.
Analytical interpretation
Use the source-reviewed guide to separate chromatographic area purity, quantitative assay, LC-MS identity, composition and stability evidence before comparing variants or requesting a lot record.
Open the Quality & Documentation HubHPLC area ≠ assayA dominant peak does not establish target mass fraction.
Intact mass ≠ full sequenceIdentity strength depends on resolution and orthogonal evidence.
Counterions affect contentWater, salt form and solvents change the as-is composition.
Storage needs a data basisShipping practice is not the same as stability evidence.
Evidence map
Published studies and regulatory records, not customer testimonials or usage guidance.
The public record is limited and does not provide the breadth of independent replication expected for a general claim.
View primary recordGene-expression outcomes are mechanistic and do not establish clinical benefit.
View primary recordThird-party publications selected for direct relevance.
Regional clinical report. 2015. PMID 26356395.
Experimental study. 2016. PMID 26924987.
Concise answers for researchers comparing identity, evidence and catalog variants.
The clearest human report is a regional randomized trial in anxiety-disorder patients, where Selank was added to a standard anti-anxiety medicine, not used alone. That combination was linked to somewhat faster improvement and fewer typical tranquilizer side effects like sedation, attention and memory problems, and fatigue. Animal work separately showed changes in GABA-related gene activity in rat brain. These findings are exploratory and do not establish Selank as a stand-alone treatment. Replication outside that region is limited.
Available evidence includes a small regional human trial, animal gene studies, and earlier cell and behavioral work. These cannot establish broad anti-anxiety effectiveness, international approval, or that any research catalog lot matches a clinically tested preparation. Clinical Selank, where it exists, is a distinct product with its own manufacturing and regulatory status. This catalog material is supplied for research, development, and manufacturing use only. Lot quality is controlled by product-specific analytical documents, not by published study results.
The literature includes mechanistic cell work, rodent studies and limited human reporting with important accessibility and replication limits.
No. The cited records describe their own intervention, formulation, model and controls. They do not verify the identity, purity, sterility, safety or efficacy of a catalog lot.
A lot-specific COA, product specification sheet and analytical method summary can be requested where applicable.
Store at -20 °C, protected from light and moisture. After reconstitution, aliquot and avoid repeated freeze-thaw cycles. Confirm the applicable storage statement on the product-specific specification and lot documentation.
Knowledge center
Owned educational content connected to this family.
Selank has limited human comparative literature and a larger mechanistic narrative around GABA signaling. The human reports are small, mostly Russian-language, and do not…
Updated October 13, 2026
Selank is the heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro. It incorporates the tuftsin sequence Thr-Lys-Pro-Arg and adds Pro-Gly-Pro, but it is not identical to tuftsin.
Updated October 1, 2026Knowledge tools
Move from this dossier into canonical evidence maps, verified status records, analytical interpretation and laboratory calculations.
Claims were checked against the linked primary publication, regulatory label or authoritative compound record. Published findings stay attached to their study model, formulation and route. Catalog identity and lot quality remain controlled by the applicable specification and lot-specific documents.
Technical procurement
Selected: SK5 · 5 mg × 10 vials
Tell us what you need. Your enquiry will be routed to the appropriate contact for catalog numbers, availability and quotation details.
